Pharmacologically directed design of leukemia therapy.
作者： W. Plunkett , V. Heinemann , E. Estey , M. Keating
DOI: 10.1007/978-3-642-74643-7_111
关键词:
摘要: The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response pharmacokinetics Ara-CTP in leukemia cells during therapy. Knowledge cellular pharmacology has been used optimize dose rates design combination treatment schedules. An understanding pharmacodynamics other drugs is likely be useful parameter for planning protocols.
springer.com
sci-hub.st 参考文章(14)
William Plunkett, Donna S. Shewach, Cellular Retention of 9-β-d-Arabinofuranosyladenine 5′-Triphosphate and the Pattern of Recovery of DNA Synthesis in Chinese Hamster Ovary Cells Cancer Research. ,vol. 46, pp. 1581- 1584 ,(1986)
V Heinemann, E Estey, M J Keating, W Plunkett, Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. Journal of Clinical Oncology. ,vol. 7, pp. 622- 628 ,(1989) , 10.1200/JCO.1989.7.5.622
Volker Heinemann, David Murray, Ronald Walters, Raymond E. Meyn, William Plunkett, Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemotherapy and Pharmacology. ,vol. 22, pp. 205- 210 ,(1988) , 10.1007/BF00273412
Hagop M. Kantarjian, Elihu H. Estey, William Plunkett, Michael J. Keating, Ronald S. Walters, Stephen Iacoboni, Kenneth B. McCredie, Emil J. Freireich, Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia The American Journal of Medicine. ,vol. 81, pp. 387- 394 ,(1986) , 10.1016/0002-9343(86)90287-1
William Plunkett, Stephen Iacoboni, Michael J. Keating, CELLULAR PHARMACOLOGY AND OPTIMAL THERAPEUTIC CONCENTRATIONS OF 1‐β‐D‐ARABINOFURANOSYLCYTOSINE 5‘‐TRIPHOSPHATE IN LEUKEMIC BLASTS DURING TREATMENT OF REFRACTORY LEUKEMIA WITH HIGH‐DOSE 1‐β‐D‐ARABINOFURANOSYLCYTOSINE Scandinavian Journal of Haematology. ,vol. 36, pp. 51- 59 ,(2009) , 10.1111/J.1600-0609.1986.TB01590.X
Bayard D. Clarkson, Frederick S. Philips, Zalmen Arlin, Ting-Chao Chou, Metabolism of 1- β -d-Arabinofuranosylcytosine in Human Leukemic Cells Cancer Research. ,vol. 37, pp. 3561- 3570 ,(1977)
Hagop Kantarjian, Michael J. Keating, William Plunkett, Elihu Estey, Theresa M. Adams, Billie Nowak, Jan O. Liliemark, Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy Cancer Research. ,vol. 47, pp. 3005- 3011 ,(1987)
William Plunkett, Donna S. Shewach, Donna S. Shewach, Correlation of Cytotoxicity with Total Intracellular Exposure to 9-β-d-Arabinofuranosyladenine 5′-Triphosphate Cancer Research. ,vol. 42, pp. 3637- 3641 ,(1982)
Jan O. Liliemark, William Plunkett, Dennis O. Dixon, Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine Cancer Research. ,vol. 45, pp. 5952- 5957 ,(1985)
William Plunkett, Elihu Estey, Elihu Estey, Jan O. Liliemark, Jan O. Liliemark, Michael J. Keating, Michael J. Keating, Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Seminars in Oncology. ,vol. 14, pp. 159- 166 ,(1987) , 10.5555/URI:PII:0093775487900613